Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as an oral tablet for oral use. It treats chronic myeloid leukemia in adult patients and is employed as part of conditioning regimens for bone marrow or stem cell transplantation.

GNH USA supplies Myleran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Deliveries are coordinated through a network of certified partners to ensure timely access.

Busulfan is an alkylating antineoplastic agent used in hematologic malignancies and transplant conditioning.

Chronic Myeloid Leukemia: reduces leukemic cell proliferation and helps achieve disease control. Bone Marrow Transplant Conditioning: provides myeloablative effect to facilitate donor graft engraftment. Stem Cell Transplant Conditioning: creates immunosuppression and marrow ablation for successful stem cell engraftment.

Busulfan may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Oral mucositis - Low blood counts (neutropenia, thrombocytopenia)

Serious or Rare Side Effects: - Pulmonary fibrosis - Hepatic veno‑occlusive disease - Seizures - Severe bone marrow suppression

When using Myleran, careful monitoring and specific precautions are required.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess liver function: evaluate hepatic enzymes before and during therapy. Avoid in pregnancy: drug is contraindicated due to fetal risk. Use anticonvulsant prophylaxis: consider seizure prophylaxis in high‑risk patients. Adjust dose in renal/hepatic impairment: follow prescriber guidance. Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Busulfan interacts with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Concomitant use with other alkylating agents: increased toxicity. - Concurrent azathioprine or cyclophosphamide: additive myelosuppression. - Strong CYP2C9 inhibitors (e.g., fluconazole): increased busulfan exposure.

Moderate Interactions (Monitor Closely): - Anticonvulsants (phenytoin, carbamazepine): may lower busulfan levels. - Acetaminophen: may affect metabolism. - NSAIDs: may increase bleeding risk due to thrombocytopenia.